Genomic Cancer Panel And Profiling Market Report 2026

Genomic Cancer Panel And Profiling Market Overview

• Genomic Cancer Panel And Profiling market size has reached to $10.28 billion in 2025 • Expected to grow to $15.45 billion in 2030 at a compound annual growth rate (CAGR) of 8.4% • Growth Driver: Rising Cancer Incidence Driving The Growth Of The Market Due To Aging Population And Improved Detection • Market Trend: Enhancing Diagnostic Accuracy Through Technological Integration • North America was the largest region in 2025.

What Is Covered Under Genomic Cancer Panel And Profiling Market?

Genomic cancer panel and profiling is a molecular diagnostic technique that analyzes multiple genes simultaneously to detect genetic mutations, alterations, or biomarkers associated with cancer. Its primary purpose is to guide personalized treatment decisions, predict disease progression, and improve cancer diagnosis and monitoring. The main tissue testing types in the genomic cancer panel and profiling market are solid tissue testing and liquid tissue testing. Solid tissue testing is a diagnostic procedure that analyzes samples from solid tumors or organs to identify genetic mutations, biomarkers, or disease characteristics. Various technologies are used in this process, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in-situ hybridization (FISH), immunohistochemistry (IHC), and others, with cancer panels including single-gene panels and multi-gene panels. These tests are used in a variety of applications, including clinical and research settings, by end users such as hospitals, research and academic institutes, clinical and diagnostic laboratories, and other end users.

What Is The Genomic Cancer Panel And Profiling Market Growth Forecast?

The genomic cancer panel and profiling market size is expected to see strong growth in the next few years. It will grow to $15.45 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to expansion of companion diagnostics, growth in liquid biopsy adoption, integration of ai in genomic analysis, increasing oncology screening programs, development of cost-effective sequencing platforms. Major trends in the forecast period include increasing adoption of multi-gene cancer panels, rising use of next-generation sequencing, expansion of liquid biopsy testing, growing demand for personalized oncology, integration of genomic data in clinical decision-making.

Global Genomic Cancer Panel And Profiling Market Segmentation

1) By Tissue Testing: Solid Tissue Testing, Liquid Tissue Testing 2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Other Technologies 3) By Cancer Panel Type: Single-Gene Panel, Multi-Gene Panel 4) By Application: Clinical, Research 5) By End User: Hospitals, Research And Academic Institutes, Clinical And Diagnostic Laboratories, Other End Users Subsegments: 1) By Solid Tissue Testing: Biopsy Samples, Surgical Resection Samples, Formalin-Fixed Paraffin-Embedded (FFPE) Tissues, Fresh Frozen Tissues 2) By Liquid Tissue Testing: Blood, Urine, Saliva, Cerebrospinal Fluid (CSF), Other Bodily Fluids

What Is The Driver Of The Genomic Cancer Panel And Profiling Market?

Rising cancer incidence is expected to propel the growth of the genomic cancer panel and profiling market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body. The rise in cancer incidence is due to an aging population, which increases the likelihood of developing cancer as life expectancy continues to grow. Genomic cancer panels and profiling support oncology care by identifying genetic mutations and biomarkers, enabling personalized treatment strategies, and improving early detection and monitoring.For instance, in January 2024, according to the American Cancer Society, a U.S.-based nonprofit organization, in 2022, around 20 million new cancer cases were reported globally, resulting in 9.7 million deaths; driven primarily by population growth, the global cancer burden is projected to rise to 35 million cases by 2050. Therefore, rising cancer incidence will drive the growth of the genomic cancer panel and profiling industry.

Key Players In The Global Genomic Cancer Panel And Profiling Market

Major companies operating in the genomic cancer panel and profiling market are Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, ARUP Laboratories, Tempus Labs, Genscript Biotech Corporation, NeoGenomics Inc., Foundation Medicine, Invitae Corporation, Guardant Health Inc., Caris Life Sciences, Fulgent Genetics, NanoString Technologies Inc., Genecast Biotechnology Co. Ltd, Burning Rock DX, HTG Molecular Diagnostics Inc., Predictive Oncology Inc.

Global Genomic Cancer Panel And Profiling Market Trends and Insights

Major companies operating in the genomic cancer panel and profiling market are focusing on technological advancements such as next-generation sequencers to improve the accuracy, speed, and comprehensiveness of cancer diagnostics and enable more personalized treatment decisions. Next-generation sequencers are advanced DNA sequencing technologies that enable rapid, high-throughput analysis of genetic material to identify mutations, variations, and other genomic features. For instance, in April 2025, QIAGEN N.V., a Netherlands-based biotechnology company, launched QIAseq panels designed for next-generation sequencers, enabling comprehensive genomic profiling by analyzing over 700 genes. These panels are intended for both research and clinical applications, aiming to improve cancer diagnostics and treatment strategies.

What Are Latest Mergers And Acquisitions In The Genomic Cancer Panel And Profiling Market?

In June 2023, Quest Diagnostics, a US-based clinical laboratory company, acquired Haystack Oncology for an undisclosed amount. Through its acquisition, Quest Diagnostics expanded its capabilities in liquid biopsy and cancer detection, enhancing its genomic testing offerings. Haystack Oncology is a US-based biotech company focused on developing innovative liquid biopsy technologies for early cancer detection and monitoring.

Regional Insights

North America was the largest region in the genomic cancer panel and profiling market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Genomic Cancer Panel And Profiling Market?

The genomic cancer panel and profiling market consists of revenues earned by entities by providing services such as genetic mutation analysis, companion diagnostic testing, cancer risk assessment, and screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The genomic cancer panel and profiling market also includes sales of targeted gene panels, companion diagnostic kits, sequencing platforms and instruments, bioinformatics software, and analysis tools. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Genomic Cancer Panel And Profiling Market Report 2026?

The genomic cancer panel and profiling market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the genomic cancer panel and profiling industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.